lobbying_activities: 1594293

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1594293	9774d8c9-c2d7-419c-bf6e-8b8ef4966a1b	Q3	BROWN RUDNICK LLP	287895	APOTEX CORPORATION	2014	third_quarter	PHA	Issues relating to Risk Evaluation and Mitigation Strategy programs; Generic Drug User Fee Amendments of 2012 (GDUFA); Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).	HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2014-10-17T15:21:56.507000-04:00